IFNL4 and COVID-19: The frequencies of IFNL4 rs11322783 genotypes in the patients with COVID-19 (n = 128) and a validated data set of European healthy controls (n = 14152) [31] were as follows: TT/TT 41.4% (n = 53) vs. 45%, TT/ΔG 47.7% (n = 61) vs. 44.2% and ΔG/ΔG 10.9% (n = 14) vs. 10.8%; there was no statistically significant difference in the distribution of IFNL4 genotypes (p > 0.05 for all the measurements).